Key Drivers
- Strong cash generation
- Tight liquidity
- High leverage
AIAI Summary
CI is no longer just a defensive healthcare hold; strong earnings growth, raised guidance, and robust free cash flow make it a capital-return story, but with CEO succession, portfolio cleanup, and a thin liquidity cushion, investors should only stay constructive if management keeps pharmacy-cost pressure and execution risks under control.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong cash generation
- •Tight liquidity
- •High leverage
CI generates strong earnings and cash flow at a reasonable valuation, but thin liquidity and elevated leverage limit financial flexibility.
Price Behavior
Key Price Behavior Insights:
- •Failed breakout
- •Support test
- •Momentum cooled
CI remains constructively higher over the last month, but the failed breakout above $300 and quick pullback to $281-$283 suggest momentum has cooled and support is now the key near-term test.
Sharp reversal after the recent peak, with two down sessions pulling price back from above $300
Sentiment & News
Key News Insights:
- •Guidance raise
- •Evernorth strength
- •Portfolio pruning
Cigna reported strong Q1 results with higher revenue and EPS, raised 2026 guidance, and is tightening its portfolio through an exchange exit, eviCore review, and continued capital returns.
The news is supportive for Cigna's stock, reinforcing earnings momentum and valuation upside while signaling a more focused business mix
Similar Companies in Healthcare
Other companies in the same sector with AI ratings